New Zealand is one of only two countries in the world that allows direct-to-consumer (DTC) advertising. Such advertising has increased dramatically since the mid-1990s, and a wide range of promotional activities currently takes place. Compliance with the legislation occurs through an industry body that hears complaints over alleged breaches. The weakness of the organized consumer sector in the country means there is a paucity of complaints, yet a self-regulating system is reliant on complaints for compliance. The author describes the unsatisfactory experience of taking a complaint and examines the argument that DTC advertising provides consumers with important information. The author measures DTC advertising against criteria for quality health information and finds it wanting.
Get full access to this article
View all access options for this article.
References
1.
Advertising Standards Authority (2002), “Therapeutic Advertising Pre-vetting System,” (accessed July 3, 2002), [available at www.asa.co.nz/taps.htm].
BonaccorsoSilvia N., and SturchioJeffrey L. (2002), “Direct to Consumer Advertising Is Medicalising Normal Human Experience: Against,”British Medical Journal, 324(April 13), 910–11.
4.
Boston Women's Health Book Collective (1971), Our Bodies, Ourselves.New York: Simon & Schuster.
5.
BudgeR. Claire, StephensChristine, and CarryerJenny (2000), “Decision Making: New Zealand Women Speak About Doctors and HRT,”New Zealand Family Physician, 27(6), 41–47.
6.
BruntonColmar (2000), “Perceptions of Diane-35 Print Advertisement,” research prepared for Pharmaceutical Management Agency, Auckland, New Zealand.
ConeySandra (1991), The Menopause Industry: A Guide to Medicine's ‘Discovery’ of the Mid-life Woman.Auckland, New Zealand: Penguin.
9.
ConeySandra (1994), “NZ Review of Drug Prescribing Advertising,”The Lancet, 344(November 12), 353–54.
10.
ConeySandra (2002), “Blood Clots on Diane-35 and Estelle-35,”Women's Health Update, 6(1), 1–2.
11.
CoulterAngela, EntwhistleVikki, and GilbertDavid (1998), Informing Patients: An Assessment of the Quality of Patient Information Materials.London: King's Fund.
EDEN News (1999), “Xenical Advertisement Successfully Stopped,” 3 (December), 1.
14.
EntwhistleVikki A., SheldonT.A., SowdenA.J., WattI.S. (1996), “Supporting Consumer Involvement in Decision-Making: What Constitutes Quality in Consumer Health Information?”International Journal of Quality in Health Care, 8(5), 425–37.
15.
EssexCharles (1994), “Television Drug Advert Causes Upset in New Zealand,”British Medical Journal, 309(November 5), 1184–85.
16.
HoekJanet, and GendallPhillip (2002), “Direct-to-Consumer Advertising Down Under: An Alternative Perspective and Regulatory Framework,”Journal of Public Policy & Marketing, 21(Fall), 202–12.
17.
HoffmanJerome R., and WilkesMichael (1999), “Editorial: Direct to Consumer Advertising of Prescription Drugs,”British Medical Journal, 318(May 15), 1301–02.
18.
HolmerAlan F. (2002), “Direct-to-Consumer Advertising: Strengthening Our Health Care System,”New England Journal of Medicine, 346(February 14), 526–28.
19.
MartindaleSusan (2002), Medsafe, personal telephone communications, (June 24 and 25).
20.
McBrideTim (2002), personal telephone communication, (June 26).
21.
Medsafe (2002), A Proposal for a Trans Tasman Agency to Regulate Therapeutic Products: Discussion Paper.Wellington, New Zealand: Medsafe.
22.
Minister of Health (2001a), The New Zealand Health Strategy.Wellington, New Zealand: Ministry of Health.
23.
Minister of Health (2001b), “Direct-to-Consumer Advertising Rules Will Become Strict,” media statement, (posted August 14), (accessed June 26, 2002), [available at www.beehive.govt.nz/ViewDocument.cfm?DocumentID=11517].
24.
Ministry of Health (1994), Medicines and Medical Devices: Discussion Paper on the Review of the Medicines Legislation.Wellington, New Zealand: Ministry of Health.
25.
Ministry of Health (1995), Medicines Medical Devices and Dietary Supplements: Report of the Analysis of Submissions on Proposals to Reform the Regulation of Therapeutic Products.Wellington, New Zealand: Ministry of Health.
26.
Ministry of Health (2000), Direct-to-Consumer Advertising of Prescription Medicines in New Zealand: A Discussion Paper.Wellington, New Zealand: Ministry of Health.
27.
Ministry of Health (2001a), Health Report: Direct-to-Consumer Advertising of Prescription Medicines: Policy Options, (August 16), File Ref: TT 05-18-11-0, (accessed June 25, 2002), [available at http://www.executive.govt.nz/minister/king/dtca/01.htm].
28.
Ministry of Health (2001b), Summary of Submissions on the Direct-to-Consumer Advertising of Prescription Medicines in New Zealand: Discussion Paper.Wellington, New Zealand: Ministry of Health.
29.
MintzesBarbara (1998), Blurring the Boundaries: New Trends in Drug Promotion.Amsterdam, The Netherlands: HAI-Europe.
30.
MintzesBarbara (2001), “Direct-to-Consumer Prescription Drug Advertising: The European Commission's Proposals for Legislative Change,” (December). Amsterdam, The Netherlands: Health Action International (HAI-Europe).
31.
MintzesBarbara (2002), “Direct to Consumer Advertising Is Medicalising Normal Human Experience: For,”British Medical Journal, 324(April 13), 908–909.
32.
National Institute for Health Care Management Research and Educational Foundation (2001), Prescription Drugs and Mass Media Advertising, 2000.Washington, DC: National Institute for Health Care Management Research and Educational Foundation.
33.
Pharmaceutical Management Agency (2002), Supplied data on Drug Costs, Prescription Numbers, and Pharmaceuticals Manufacturers’ Expenditure on Advertising, Wellington, New Zealand.
34.
RosenthalMeredith B., BerndtErnst R., DonohueJulie M., FrankRichard G., and EpsteinArnold M. (2002), “Promotion of Prescription Drugs to Consumers,”New England Journal of Medicine, 346(February 14), 498–505.
35.
SmithMegan (2002), Letter to support groups from Xeloda Product Manager, Roche Products (New Zealand) Ltd, (April 18).
36.
Statistics New Zealand (2002), Average Ordinary Time Weekly Earnings, (accessed June 26), [available at www.statisticsnz.govt.nz].
37.
Vasilakis-ScaramozzaCatherine, and JickHershel (2001), “Risk of Venous Thromboembolism with Cyproterone or Levenorgestrel Contraceptives,”The Lancet, 358(October 27), 1427–29.
38.
WatsonRory (2001), “Consumer Groups Fight Plans for ‘Direct-to-Patient’ Drug Advertisements,”British Medical Journal, 323(November 20), 889.
WolfeSidney M. (2002), “Direct-to-Consumer Advertising: Education or Emotion Promotion,”New England Journal of Medicine, 346(February 14), 524–26.
42.
WoloshinSteven, SchwartzLisa M., TremmelJennifer, and Gilbert WelchH. (2001), “Direct-to-Consumer Advertising for Prescription Drugs: What Are Americans Being Sold?”The Lancet, 358(October 6), 1141–46.
